HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neonatal outcome after pregnancy complicated by abnormal velocity waveforms in the umbilical artery.

Abstract
The neonatal outcome of 61 infants born after pregnancies complicated by absent or reversed end diastolic flow velocities (AREDFV) in the fetal umbilical artery was compared with that of 61 controls matched for gestational age born after high risk pregnancies with documented forward end diastolic flow velocities (EDFV). The AREDFV group was significantly more growth retarded, had lower platelet counts at birth, and were more likely to become significantly thrombocytopenic in the first week after birth. Owing to concerns about the possible increased risk of necrotising enterocolitis in newborn infants after AREDFV, this group was started on enteral feeds later and was more likely to receive parenteral nutrition than the EDFV group. Seven infants with AREDFV and one control infant developed necrotising enterocolitis.
AuthorsM McDonnell, V Serra-Serra, G Gaffney, C W Redman, P L Hope
JournalArchives of disease in childhood. Fetal and neonatal edition (Arch Dis Child Fetal Neonatal Ed) Vol. 70 Issue 2 Pg. F84-9 (Mar 1994) ISSN: 1359-2998 [Print] England
PMID8154919 (Publication Type: Comparative Study, Journal Article)
Topics
  • Adolescent
  • Adult
  • Blood Flow Velocity
  • Enteral Nutrition
  • Enterocolitis, Pseudomembranous (complications, therapy)
  • Female
  • Fetal Growth Retardation (complications)
  • Humans
  • Infant, Newborn
  • Male
  • Platelet Count
  • Pregnancy
  • Pregnancy Complications, Cardiovascular (physiopathology)
  • Pregnancy Outcome
  • Thrombocytopenia (complications)
  • Umbilical Arteries (physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: